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S376 Poster Session IIother management strategies. Associated increases in MAP, weight,
and serum creatinine at the time of PRES compared to baselinemea-
surements exemplify the importance of possible prevention through
more aggressive blood pressure and fluid management strategies in
this patient population.
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A COMPARISON OF CALCULATED GLOMERULAR FILTRATION RATE (GFR)
VS. MEASURED GFR IN A BLOOD AND MARROW TRANSPLANT POPULA-
TION
Shapiro, J.F.1, Ho, V.1, Wetzstein, G.1, Woodard, A.1, Rawal, B.2,
Pidala, J.3 1H. Lee Moffitt Cancer Center, Tampa, FL; 2H. Lee Moffitt
Cancer Center, Tampa, FL; 3H. Lee Moffitt Cancer Center, Tampa, FL
One of the most controversial topics in clinical practice is the es-
timation of a patient’s creatinine clearance (CrCl) and determination
of renal function. The gold standard in determining the glomerular
filtration rate (GFR) involves a 24 hour urine collection, which can
be onerous to patients and potentially inaccurate. As a result, the
most common method to determine GFR utilizes the Cockcroft-
Gault equation (CG) and Modification of Diet in Renal Disease
(MDRD) equation. One limitation with the CG equation is the de-
bate regarding which weight should be utilized.
Up until January 2010, a 24 hr collected CrCl was standard prac-
tice at Moffitt Cancer Center (MCC) for patients undergoing hema-
topoietic cell transplant (HCT) to assess patients’ renal function.
Because of the potential concerns with the collected 24 hour CrCl,
the department decided to calculate GFR utilizing the CG equation.
We performed a retrospective analysis to assess whether calculated
CrCl using actual, adjusted, or ideal bodyweight best correlated with
CrCldeterminedby 24hoururine collection.TheHCTdatabasewas
queried for all patients transplanted atMCCbetween January 1, 2009
throughDecember 31, 2009. From a total 355 patients, we randomly
selected 200 autologous and allogeneic patients for evaluation.
The correlation between the calculated CrCl based on actual, ad-
justed, and ideal body weight and collected CrCl was determined.
Pearson correlation coefficients of log-transformed data are pre-
sented in Table 1.The magnitude of correlation was greatest for
CrCl based on ideal body weight and collected CrCl, and statistical
comparison between competing approaches for calculated CrCl (ac-Table 1. Pearson Correlation Coefficients, N 5 200
L_CrCl_Actual L_CrCl_Ideal L_CrCl_Adj L_Collected_CRCl
L_CrCl_Actual* 1.00000 0.81541 p < 0.0001 0.96953 p < 0.0001 0.60256 p < 0.0001
L_CrCl_Ideal^ 0.81541 p < 0.0001 1.00000 0.92888 p < 0.0001 0.71345 p < 0.0001
L_CrCl_Adj& 0.96953 p < 0.0001 0.92888 p < 0.0001 1.00000 0.67072 p < 0.0001
L_Collected_CRCl 0.60256 p < 0.0001 0.71345 p < 0.0001 0.67072 p < 0.0001 1.00000
L5 log-transformed data; *5 Creatinine clearance based off of actual body weight; ^5 Creatinine clearance based off of ideal body weight; &5 Cre-
atinine clearance based off of adjusted body weight.cording to actual, adjusted, or ideal body weight) confirmed that the
correlation between ideal bodyweight and collectedwas significantly
greater than that for either actual (p \ 0.0001) or adjusted (p \
0.0001).
These data indicate that ideal body weight-based calculated creat-
inine clearance most closely approximates collected creatinine clear-
ance. Based on these results, we recommend ideal body weight for
such calculations for dosing of conditioning chemotherapy and im-
mune suppressive agents following HCT.
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PHARMACY DRIVEN POSACONAZOLE THERAPEUTIC MONITORING IN
A LEUKEMIA AND BONE MARROW TRANSPLANT CENTER
Leech, M.1, LaPorte, J.1, Mihelic, R.1, Sanacore, M.1, Sizemore, C.1,
Zhang, X.2, Penland, P.1, Holland, H.K.2, Morris, L.E.2,
Solomon, S.R.2, Bashey, A.2 1Blood and Marrow Transplant Program,
Northside Hospital, Atlanta, GA; 2Blood and Marrow Transplant Group
of Georgia, Atlanta, GA
Objectives: Posaconazole (POS) is an extended-spectrum triazole
with proven efficacy for antifungal prophylaxis in patients (pts) un-dergoing HSCT or treatment of acute leukemia. The FDA recom-
mends a goal POS average serum drug concentration of .700 ng/
ml. We implemented a pharmacy-driven POS therapeutic monitor-
ing program. Our primary objective was to see if pharmacy interven-
tion can be helpful in optimizing attainment of therapeutic POS
levels.
Methods: Forty-eight steady-state plasma trough POS levels (33 in
HSCT pts, 15 in pts undergoing acute leukemia therapy) performed
after at least 7 days of administration were analyzed.
Results: POS levels were .700 ng/ml in 19/48 (40%) pts. Mean
POS level was 790 ng/ml (range 53- 2960), and median was 602
ng/ml. Of the 29 levels\700ng/ml, there were 26 dose modifica-
tions. POS was changed to another antifungal in 13 pts, POS was
discontinued in 2 pts, and dose was increased in 11 pts. Of the 11
increased doses, 8 follow up levels were drawn with 4 pts achiev-
ing a documented therapeutic level. POS was being used as pro-
phylaxis (starting dose 200mg TID) in 31 pts (65%) and
empirically (starting dose 400mg BID) in 17 pts (35%). The high-
est dose used was 400mg QID in one pt with documented fungal
infection.
GVHD was present in 16 of 33 HSCT pts (48%), and ten of the
pts had gut GVHD at the time of level. POS levels were .700ng/
mL in 6/16 (38%) and 2/10 (20%) of all GVHD and gut GVHD
pts, respectively, although this was not statistically signficant. Pro-
ton-pump inhibitor or H2 antagonist therapy (PPI/H2) was admin-
istered concurrently with 42/48 (88%) of levels, although the use of
these drugs had no apparent effect on therapeutic levels. Leukemia
pts were significantly less likely to achieve therapeutic POS levels
when compared to HSCT pts (27% vs 61%, p 5 0.029). Other
than treatment group, we found no other factors that correlated
with achieving therapeutic levels.
Conclusion: The pharmacy based implementation of POS thera-
peutic monitoring revealed that achievement of recommended
POS levels remains a challenge in an unselectedHSCT and leukemic
population. This program enabled documentation of compliance
and allowed an attempt at improvement of POS levels by dose adjust-
ment. Pharmacists counseled pts on ways to increase absorption by
taking with a high fat meal, nutritional supplement, or acidic carbon-
ated beverage, and by stopping their PPI/H2.470
REDUCED-DOSE MELPHALAN VS. STANDARD DOSE MELPHALAN FOR
AUTOLOGOUS STEM CELL TRANSPLANTATION: IS THERE A DIFFERENCE
IN OUTCOME?
Maewal, I.1, Gulbis, A.1, Champlin, R.E.2, Qazilbash, M.H.2 1MD
Anderson Cancer Center, Houston, TX; 2MD Anderson Cancer Center,
Houston, TX
Background: Based on the results of randomized phase III trials,
melphalan 200 mg/m2 IV (MEL 200) is considered the standard
preparative regimen for autologous hematopoietic stem cell trans-
plantation (auto-HCT) for multiple myeloma. However, reduced
doses of melphalan, 140 mg/m2 (MEL 140) or 180 mg/m2
(MEL 180), are often used in older patients or patients with renal
dysfunction.
Methods:The primary objective was to determine if there was a dif-
ference in toxicity, treatment-related mortality, response rate, pro-
gression-free survival or overall survival in patients that received
lower doses of melphalan for auto-HCT. From June 1, 1996 through
December 25, 2010, 1425 patients received auto-HCT at our insti-
tution. We identified 57 patients that received MEL 140 or 180 and
Poster Session II S377compared their outcomes with a control group (approximately 4:1)
of patients who received MEL 200. Patients were matched for the
year of transplant, chemosensitivity, disease status at auto-HCT
and time from diagnosis to auto-HCT.
Results: Preparative regimens were MEL 140 (19 patients),
MEL180 (38 patients) and MEL 200 (253 patients). Patients in
MEL 140 groupwere older (median age 70), with 58%patients older
than 65 at auto-HCT (p 5 0.0001). Median serum creatinine level
(1.71 mg/dl) was higher in the MEL 140 group (p 5 0.007). There
was no significant difference in disease status (p 5 0.38) or chemo-
sensitivity (p5 0.28) between the 3 groups. Median times to neutro-
phil engraftment in MEL 140, 180 and 200 were 11, 10 and 10 days,
respectively (p5 0.15). Transplant-related mortality at 100 days was
0%, 2% and 0.8% in MEL 140, 180 and 200, respectively (p5 1.0).
Complete remission (CR) + very good partial remission (VGPR)
were seen in 42%, 37% and 45% in Mel 140, 180 and 200, respec-
tively (p 5 0.45). The overall response rate (CR + VGPR + PR)
was 89%, 71% and 82% in MEL 140, 180 and 200, respectively (p
5 0.54). Median follow up in surviving patients in Mel 140, 180
and 200 was 13.8, 24.3 and 18.3 months, respectively. There was
no significant difference in time to progression (p 5 0.27) between
Mel 140, 180 or 200. Kaplan-Meier estimates of 2-year progres-
sion-free survival were 69%, 72% and 52% (p 5 0.74), and 2-year
overall survival were 69%, 83% and 83% (p 5 0.48) in Mel 140,
180 and 200, respectively.
Conclusion: The dose of melphalan can be safely reduced to 140
mg/m2 in older patients or patients with renal insufficiency without
adversely impacting the response rate, duration of remission or
survival.471
AZTREONAM AND VANCOMYCIN USE FOR EPISODES OF FEBRILE
NEUTROPENIA DURING HEMATOPOETIC STEM CELL TRANSPLANTATION
Trifilio, S., Mehta, J. Feinberg School of Medicine, Northwestern Univer-
sity and Norhtwestern Memorial Hospital
The spectrum of bacterial infections seen during febrile neutro-
penia(FN) in HSCT recipients continues to change, especially
with the emergence of multi-drug resistant organisms. Aztreona-
m(AZ) plus Vancomycin (VAN) have been used successfully for
FN in cancer patients, however the effectiveness of AZ plus
VAN for FN during HSCT is largely unknown. A retrospective
chart review was performed to determine the effectiveness of AZ
in FN.
Methods: 822 consecutive HSCT patient charts were re-
viewed(2004-2008). All patients received a minimum of 48hours of
AZ/VAN treatment for FN. Patients had received ciprofloxacin as
prophylaxis. The criteria for success was based upon evidence based
guidelines for the evaluation of new anti-infective drugs in FN
FN(CID Vol.15 Nov 1992 Suppl: 206-15) as follows:
1. Unexplained fever: defervesence within 72hr without recurrence
and no clinical s/s infection.
2. Clinically defined infection: Clinical improvement including fe-
ver, without antibiotic change or death
3. Microbiologically defined infection: All s/s and microbiological
evidence of disease eradicated without recurrence for 7days.
Results: 67 AZ treated patients were identified. Demographics: age
5 59(24-77), gender male5 29, Diagnosis: myeloma5 48, NHL5
10, AML 5 7, HSCT type: autologous 5 45. allogeneic 5 22. Me-
dian time to start AZ(post-HSCT infusion): day +8(-6-12), Number
of AZ treatment days 5 6(2-33)
Treatment Outcome
1. Unexplained fever(n5 36): Success5 26/36(73%), 2 patients died
2. Clinically defined(n 5 12): Hospital Pneumonia(n 5 9): Success
5 5/9(55%-ATB changes), Typhlitis (n 5 1) 0/1 (ATB change),
Cellulitis(n 5 1)(0/1success (ATB change)
3. Microbiologically defined infection (see Table 1): 20 patients ex-
perienced 30 episodes of microbiologically confirmed infection.
The majority (80%) were gram positive cocci blood stream infec-
tions and were successfully treated (80%-2 died). Gram negative
BS infection overall success was 50%(1died)6 patients developed clinical CDAD and 9 patients became VRE
surveillance positive shortly after AZ treatment. A non-significant
trend towards more BS infections was seen in allo-HSCT recipi-
ents(p 5 0.086)
Conclusion: AZ/VAN was effective in preventing breakthrough in-
fections for patients with unexplained fever, but less effective for pa-
tients with documented infections, requiring change or addition of
antibiotics. These results are comparable to those seen in non-
HSCT cancer patients with FN(Bodey et al.Cancer 1996 Apr1
77(7)).
Table 1. Microbiologically Defined Infection
Organism Source Successful Outcome(%)Strept Viridans blood (n 5 11) 91 (1 died-polymicrobial)
CONS(2 positive cx’s at 2sites blood (n 5 5) 80 (changed atb)
Entereococcus Faecalis blood (n 5 4) 75 (1died-polymicrobial)
MSSA blood (n 5 2) 50 (1 died-polymicrobial
E.Coli blood 5 1/
urine 5 1
BS-1 died//Urine 5 successEnterobacter urine (n 5 1) 100
Burkholderia blood 5 1 0 ( died-polymicrobial)
C.Diff stool (n 5 3) 66 (1 died-polymicrobial)472
THE IMPACT OF PRE-TRANSPLANT VALGANCICLOVIR ON EARLY CYTO-
MEGALOVIRUS REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT
Wilhelm, K., Gulbis, A., Maewal, I., Cool, R., Ferguson, J.,
Westmoreland, M., Martinez, C., Saliba, R., Rondon, G., Chemaly, R.,
Champlin, R., Kebriaei, P. The University of Texas MDAnderson Cancer
Center, Houston, TX
Background: Cytomegalovirus (CMV) reactivation is a common
complication of allogeneic hematopoietic stem cell transplant
(HSCT) occurring in up to 80% of seropositive patients. Progres-
sion to CMV disease occurs in less than 10% of patients but still car-
ries a significant risk of death. Either pre-emptive or prophylaxis
strategies are generally accepted as methods to prevent CMV dis-
ease. The use of pre-transplant ganciclovir during the conditioning
regimen followed by pre-emptive therapy has also been used in an at-
tempt to reduce the rate of early CMV reactivation, but strong data is
lacking. In this retrospective study, we evaluated the impact of pre-
transplant valganciclovir (VGC) during the conditioning regimen
followed by a pre-emptive approach on the rate of early CMV reac-
tivation after allogeneic HSCT.
Methods: This was a retrospective review of 272 patients who re-
ceived an allogeneic HSCT between 11/2008 and 1/2011. Prior to
July 2010, patients received VGC 900mg PO BID during the condi-
tioning regimen followed by a pre-emptive strategy. After July 2010,
VGC was eliminated from the pre-transplant regimen and the pre-
emptive strategy was employed alone. The no-VGCgroup was iden-
tified as consecutive patients transplanted after the change in prac-
tice. Matched controls were obtained from the 2 years prior to the
change in practice (VGC group). Controls were matched on the fol-
lowing characteristics: CMV serostatus of patient and donor, donor
type, disease, disease status, preparative regimen intensity, and age.
The primary objective was the rate of CMV reactivation through
day 100 following HSCT. CMV reactivation was defined as greater
than or equal to 3 cells by antigenemia.
Results: 136 patients in each group were evaluated. Baseline charac-
teristics were similar. The rate of CMV reactivation through day 100
was 41% in the no-VGC group compared to 46% in the VGC group
(p-value5 0.4). Median time to CMV reactivation was earlier in the
no-VGC group compared to the VGC group (26 vs 34 days; p 5
0.008). Day 100 survival (90% VGC vs 91% no-VGC; p-value 5
0.8) was similar between the groups.
Conclusion: Although the time to CMV reactivation is signifi-
cantly longer in patients who received VGC during the transplant
preparative regimen, this did not impact the rate of CMV reactiva-
tion or survival by day 100. Based on this data, this strategy is not
recommended. Newer strategies to reduce CMV reactivation are
needed.
